In our ageing society diabetes imposes a significant burden in terms of the numbers of people with the condition, diabetes-related complications including disability, and health and social care expenditure. Older people with diabetes can represent some of the more complex and difficult challenges facing the clinician working in different settings, and the recognition that we have only a relatively small (but increasing) evidence base to guide us in diabetes management is a limitation of our current approaches. Nevertheless, in this review we attempt to explore what evidence there is to guide us in a comprehensive scheme of treatment for older adults, often in a high-risk clinical state, in terms of glucose lowering, blood pressure and lipid management, frailty care and lifestyle interventions. We strive towards individualized care and make a call for action for more high-quality research using different trial designs.
Introduction and background
It is estimated that in 2017 there were 451 million (age 18-99 years) people with diabetes worldwide, and these figures are expected to increase to 693 million by 2045 [1] . A major shift in the epidemiology of diabetes has been to those aged 60-79 years [2] . Apart from this advancing tide of older people with diabetes, the ageing process itself is increasing the number of people living with the sequelae of ill health, chronic diseases, frailty and injuries, all of which enhance disability and functional decline, and pose real clinical challenges and burdens in those with Type 2 diabetes [3] . Older people with diabetes should be a priority target for focused interventions that bring about improved cardiovascular outcomes, enhanced safety and improved survival if the latter has worthwhile disability-free years and associated quality of life [4] . The important area of Type 1 diabetes in older adults is outside the scope of this review but must be addressed in due course.
We recognize that older people with diabetes can span four decades (ages 60-90 years and older), are not a homogeneous group and range from robust adults still in employment to frail residents of nursing homes. Thus, their cognitive and physical status vary widely, and they often have complex health and social care needs [4] . We therefore consider that our review of the literature in general pertains to those aged 70 years and over because the risks of comorbid illness, frailty and dependency begin to rise after this age, but we accept that other organizations may define being 'old' as less or more than 70 years [5] . It is also important to recognize that to produce valid and evidence-based recommendations for care, it is usually necessary to extrapolate research findings from clinical trials in younger adults, which is a limitation that has implications for developing clinical guidelines [6] . The modern management of older people with diabetes requires an acceptance by clinicians that recommendations of care should be tailored to the individual and take into consideration important factors such as changes in functional status, the comorbid illness profile, whether or not a person is dependent and their estimated life expectancy. These can have a marked influence on management goals, what care model is adapted, and how ongoing and follow-up care is delivered. We call this an 'individualizing care' scheme (Box 1).
Diabetes care for older people is often not straightforward for the reasons cited above, but as advancing age brings about increasing complexity of both the person with diabetes and the management of the illness itself, clinicians face greater challenges to their skills and competence. The different pathway to Type 2 diabetes in older individuals compared with younger individuals reflects changes in body composition, marked changes in insulin resistance in muscle and adipose tissues, a decrease in b-cell capacity and loss of normal insulin pulsatility, and the progressive negative effects on glucose tolerance of comorbid illness, onset of frailty and polypharmacy, all of which are superimposed on the ageing process [4, 9] . It is inevitable that some alterations or modulation of management goals will be necessary with advancing age as health risk increases and, for convenience, we have used age by decade as a way of demonstrating this. Some of the components of this pathway to diabetes and person-illness complexity are shown in Fig. 1 .
Purpose of the review
This review provides an up-to-date summary of the evidence that defines the relationship between glycaemic control and outcome in older people with Type 2 diabetes, what interventions have been undertaken that relate to glucoselowering and other care outcomes, what clinical guidance is available to enhance quality of care, and what research is needed to assist the clinician in providing evidence-based individualized diabetes care.
Review methodology
Initial screening was undertaken by each author to remove studies that were not appropriate or had no relevance to their assigned tasks within the writing group. As documented previously [10] , we used a model of methodology to conduct a comprehensive and detailed narrative review that minimizes selection bias according to the elements given below.
Data sources and search enquiry
Our detailed literature enquiry also required an assessment of relevant articles/reviews and outputs from key national and international diabetes, endocrine and clinical gerontological societies, and professional bodies. These were: Diabetes UK, American Endocrine Society, International Diabetes Federation (IDF), American Diabetes Association (ADA), Canadian Diabetes Association, European Association for the Study of Diabetes, American Medical Directors Association, British Geriatrics Society, New Zealand Society of Diabetes, Australian Diabetes Society and the American Geriatrics Society.
Databases searched were: Google Scholar, MEDLINE, CINHAL Complete and Embase. We used the following medical subject heading (MeSH) terms: older people, diabetes mellitus, aged, glucose control, guidelines, evidence base, interventions and clinical trials. We limited our selection to English language articles. The titles of all articles were reviewed for relevance. Inclusion criteria were then applied to all articles by examining abstracts, full book texts or a combination of these. A manual review of any further relevant citations was undertaken if they had been overlooked during the database searches. The authors recognize that a limitation of this search strategy is that we may be missing contributions from non-English language scientific resources and journals.
Study selection
We included studies only if the following inclusion criteria were satisfied: (1) randomized clinical trials (RCTs) or smaller clinical studies that contain information about or derived from the generic terms 'older people', 'aged', 'senior citizens' or 'elderly'; (2) they included interventional, observational or descriptive data from studies involving older people with diabetes, or data or reviews of relevant audit, diabetes care policies, or educational programmes for our defined subject population; and (3) described a range of glucose-lowering therapies or other non-pharmacological Box 1 Modern goals of diabetes care for older adults -generic to the person with diabetes, carers and health professionals [6] [7] [8] [9] Mandatory individualized management plan that takes into consideration different functional and comorbid categories, and duration of diabetes. Evidence-based prescribing for glucose-lowering agents and setting appropriate targets adjusted according to the category and wish of the person with diabetes. Proactive shared commitment to reduce the risk of cardiovascular disease and other non-cardiac vascular disorders, renal failure, visual loss, cognitive dysfunction, mobility disorder, functional decline and the development of frailty or disability. Minimize the risk of hypoglycaemia and prevent unnecessary hospitalization. Proactive monitoring to minimize the threat to independence, self-care capacity and quality of life.
What's new?
• This review represents a modern, up-to-date account of published evidence that seeks to examine the significance of previous research relating to the management of diabetes in older people.
• The review also provides a diagrammatic view of the development of the complex illness scenarios seen in ageing people with diabetes, and provides the first detailed algorithm for developing individualized care programmes in this often vulnerable group.
• The evidence review takes us through glucose-lowering trials involving older people, a discussion of important cardiovascular outcome and safety trials relevant to the elderly, in addition to a discussion of insulin therapy, lifestyle interventions and managing frailty.
• This review concludes with a call to action to promote new research in older adults with diabetes with the hope of optimizing clinical outcomes in the future. 
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State FIGURE 1 Diabetes in older adults -illness complexity leading to modulation of goals. *Provides an opportunity for screening for diabetes in highrisk groups and at opportunistic healthcare encounters. **Chronological age is only one of several factors modulating goals, but this framework represents a guide to decision-making and focusing care ª 2018 Diabetes UK treatments that sought to enhance diabetes care in older people.
Guidelines (and Position Statements) were included if they had clinical relevance to the subject population (e.g. diabetes in older people) or topic area (e.g. cardiovascular outcome), and were written by professional societies or by national or international consensus expert groups. The key issue was that guidance was designed to improve the quality of diabetes care delivered.
Data extraction
All articles/studies derived from the search enquiry were independently examined by two authors (AJS, AHA) and data were extracted using a standardized format according to their relevance to the review subject. AF and MM also independently examined all reference materials relating to glycaemic control in older people, while each intervention study was independently reviewed by the authors according to their writing group tasks. AJS and AHA independently reviewed guidelines and related material. Detailed discussion, review of any conflicts in data interpretation and mutual agreement resolved any disagreements between the reviewers. We have included data relating to the design of studies, the nature of the research question, characteristics of people involved as participants, key findings and outcomes achieved. For the intervention trials, we have included information on study design, nature of participants, the intervention used and main findings. The information obtained for the clinical guidelines reviews summarized the names of the professional organization, the main reason for the guideline development, what was the key methodology involved and how recommendations were framed.
The issue of glycaemic control -what studies tell us?
In Table 1 , we summarize the key studies that have examined the role of glycaemic control, the intensity of treatment regimens and their impact on microvascular and macrovascular complications. Although some benefits of intensive glycaemic control were seen in the prevention of microvascular complications, there were no benefits for major cardiovascular events or mortality. Although these studies primarily evaluated middle-aged people (mean age 55-65 years), subgroup analysis in the older age cohort did not show distinct differences in the role of glycaemic control. In recent years, several studies have looked specifically at older adults with diabetes. Almost all of them are observational or retrospective cohort studies.
The common themes emerging from these studies are A comprehensive review of care home diabetes, including an examination of interventions undertaken has been published recently [10] .
Summary of blood pressure and lipidlowering studies in older adults with diabetes
The active management of both hypertension and dyslipidaemia in older adults with diabetes is crucial to reduce cardiovascular risk.
People with diabetes have a high baseline cardiovascular risk and for every 1 mmHg fall in blood pressure, additional benefit is seen compared with in those without diabetes, and may be more beneficial overall than lowering of blood glucose [25] [26] [27] . Table S1 gives a detailed summary of recent studies on the cardiovascular benefits of blood pressure control in people with diabetes. In people aged ≥ 65 years (but < 85 years) with Type 2 diabetes, the evidence supports the recommendation that the target blood pressure should be < 140/90 mmHg to decrease cardiovascular disease outcomes, including stroke and progressive chronic kidney disease. Lower blood pressure targets (e.g. < 130/80 mmHg may be warranted in higher risk individuals; previous stroke or progressive chronic kidney disease with eGFR < 60 ml/min/1.73
2 ) but this would require shared decision-making with the clinician and the person with diabetes, with full discussion of the benefits and risks of each target [28] . If lower blood pressure targets are selected, careful monitoring is needed to avoid orthostatic hypotension. All the major anti-hypertensive drug classes can be used in older people with diabetes and a recent meta-analysis has shown no difference in total or cardiovascular mortality between single drug classes, but drug combinations were superior to monotherapy in reducing blood pressure and achieving better outcomes [29] . The benefits of blood pressure control in older people with diabetes are summarized in Box 2 (a).
There are no large clinical trials of statin therapy specifically designed for older people with diabetes and the evidence is based on data extrapolated from younger trial populations. In Table S2 , we give descriptions of the main studies on the cardiovascular benefits of lipidlowering in older people with diabetes. Evidence of benefit for statin therapy is generally established for those adults up to age 80 years as evidenced by the PROSPER [30] and [33] . Two large RCTs have failed to show any important cardiovascular benefits from adding fenofibrates or niacin to statin therapy in young 'elderly' populations [34, 35] . In Box 2(b), we summarize the key messages for lipid lowering and cardiovascular benefit in older adults with diabetes.
Cardiovascular benefits and the safety of older and newer glucose-lowering agents
The cardiovascular safety of glucose-lowering agents is essential in all people with diabetes, particularly older groups who are already at high clinical risk (see Fig. 2 ). Up to the end of 2017, more than 190 000 people have been studied in nine longer-term cardiovascular outcome trials, and appear to have yielded important information about the benefits and associated risks of the therapies studied. These outcome trials have involved three dipeptidyl peptidase-4 (DPP-4) inhibitor trials, four glucagon-like peptide 1 (GLP-1) receptor agonist trials and two sodium-glucose cotransporter 2 (SGLT2) inhibitor trials [36] . A comprehensive discussion of this area has been published by an expert review group [36] and the results of subgroup analyses relating to event rate by age of various cardiovascular outcome trials has also been recently examined [37] . We summarize the results of the outcome studies for both older and newer blood glucose-lowering agents in Tables S3and S4 in which we also report recently released data from the CARMELINA trial. The data did not identify any safety concerns with linagliptin of the DPP-4 inhibitor class, which provides additional reassurance for clinicians (see Ref. 9 in Table S4 ). These studies were undertaken in people with Type 2 diabetes, mainly with pre-existing cardiovascular disease, with more than three-quarters on statins, a high proportion receiving anti-hypertensive and anti-platelet medications, and a mean age of 60-65 years. Overall cardiovascular safety was demonstrated across all classes mainly using the three-point MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) as the main primary composite outcome.
In relation to prescribing glucose-lowering medication to older adults as part of an individualized approach to enhance cardiovascular protection, DPP-4 inhibitors have not shown cardiovascular benefits, whereas empagliflozin and canagliflozin (SGLT2 inhibitors) demonstrated significant reductions in cardiovascular events and renal events, with empagliflozin also reducing hospitalization for heart failure and worsening nephropathy. Time to benefit was short (< 3 months) in the EMPA-REG outcome study [38] . In relation to GLP-1 receptor agonist trials, exenatide (but not liraglutide or semaglutide) showed cardiovascular benefit in older participants (≥ 65 years) but had a 43% discontinuation rate.
A summary of the cardiovascular safety of oral glucoselowering agents in older people with diabetes is given in Box 3.
Insulin therapy in older adults
In general, several small studies have helped guide therapy recommendations in older adults with diabetes [43] . Insulin therapy has a higher risk of hypoglycaemia in older adults compared with most of the oral hypoglycaemic agents [44, 45] . However, it is possible to decrease the risk of hypoglycaemia and associated harm by carefully choosing the insulin preparation to match the timing of hyperglycaemia and by matching the coping ability of the person with diabetes to the complexity of the insulin [46] . The relative contribution of basal hyperglycaemia is lower, and that of postprandial hyperglycaemia higher in older people with diabetes compared with their younger counterparts [47] , suggesting that different therapeutic approaches may be required to treat hyperglycaemia effectively in these different age groups. In a small randomized trial of older adults (≥ 65 years), addition of morning daily glargine with oral agents was found to improve hyperglycaemia and decrease the risk of hypoglycaemia compared with mixed insulin twice a day [48] . A target systolic blood pressure around 140 mmHg is reasonable. Lower target < 130 mmHg may have benefit of reducing stroke risk but is associated with increased adverse events -requires a shared decision approach. High risk of adverse events exists in older people with recurrent falls, cognitive dysfunction or frailty. Targets are best based on level of function with tight control in the fit but relaxed in frail individuals (145-160/90 mmHg). All major anti-hypertensive classes have similar efficacy and achieving target blood pressure is more beneficial than a single class effect.
(b)
Older people with diabetes up to the age of 80 years will benefit from cholesterol-lowering treatment. Older people with diabetes are likely to benefit more than younger people due to their higher baseline risk. There is some evidence from observational trials that cholesterol lowering may be beneficial in people aged 80-85 years. There is no extra benefit of additional fenofibrate or niacin to statin therapy. See Tables S1 and S2.
Box 3 Summary of cardiovascular safety of hypoglycaemic medications
Older agents
Metformin: collectively shows modest cardiovascular benefits and evidence of safe use in various organ dysfunctions. Sulfonylureas: controversial cardiovascular benefits/risks but likely neutral. Glinides and a-glucosidase inhibitors: cardiovascular benefits when added to metformin. Thiazolidinediones (TZDs): rosiglitazone has had mixed concerns in terms of cardiovascular risk and remains suspended in Europe; pioglitazone use associated with a reduction in major adverse cardiovascular events and in all-cause mortality, and a lowered risk in recurrent stroke. The increased risk of heart failure remains an important concern.
Newer agents
Dipeptidyl peptidase-4 (DPP-4) inhibitors: neutral cardiovascular effects. Saxagliptin associated with a significant increase in heart failure hospitalization in the SAVOR-TIMI trial [1.27 (1.07-1.51)] with a trend to an increased risk of heart failure in the alogliptin EXAMINE trial. Glucagon-like peptide-1 (GLP-1) receptor agonists: liraglutide demonstrates a significant reduction in three-point MACE in the LEADER Trial but subgroup analysis of people aged 60 years and above showed no benefit; exenatide showed cardiovascular benefits in older participants on subgroup analysis of the EXSCEL trial. Some recent concerns noted about liraglutide in people with chronic heart failure and reduced left ventricular function [39] . Sodium-glucose cotransporter-2 (SGLT2) inhibitors: empagliflozin (EMPA-REG) and canagliflozin (CANVAS) show significant reductions in the three-point MACE in older participants, and a reduction in hospitalization for heart failure shown in the overall analysis of the studies.
Note: previous studies in Type 2 diabetes have shown that both insulin glargine [ORIGIN Study [40, 41] ; people with dysglycaemia, mean age 63.5 years] and insulin degludec [DEVOTE trial [42] ; people with a high cardiovascular risk, mean age 65 years] have no effects on MACE outcomes.Also see Cefalu et al. [36] and Tables S3 and S4. ª 2018 Diabetes UK The availability of various basal insulin with a half-life of 24 h or longer, including insulin glargine, degludec, glargine U300 and detemir, has provided much needed options to lower baseline glucose levels with a once-a-day injection in addition to non-insulin agents. Comparisons of different types of insulin preparations have shown mostly comparable efficacy in older adults. Some insulins such as degludec and glargine U300 have shown a better risk profile with lower risk of hypoglycaemia and less weight gain compared with glargine [49, 50] .
Methods of insulin administration have also been a topic of research in older adults. There appear to be no benefits of using a different modality such as an insulin pen, insulin pump or vial/syringe on glycaemic control in older populations. However, vision impairment and low dexterity due to arthritis may impede use of a vial/syringe in frail older adults. It has been long recognized that pre-filled insulin pens are safe and effective for older adults [51, 52] . In institutionbased diabetes care, various factors related to the institution, staff, person with diabetes and medication lead to the use of pen injectors as a preferred mode of insulin delivery to improve care and cost [53] .
The place of recent international clinical guidelines
There is a paucity of clinical intervention trials in older people with diabetes and optimal metabolic targets in this
Individualized diabetes care
(see Figure 1) • Set glycaemic targets by shared decision-making [54] . This was based on results from the UKPDS study, which included relatively younger people with fewer comorbidities and a new diagnosis of diabetes [55] . However, the more recent ACCORD, ADVANCE and VADT studies, which included a cohort of older people with more comorbidities and longer duration of diabetes, failed to demonstrate that tight glycaemic control will reduce cardiovascular mortality and in fact, significantly increase the risk of hypoglycaemia [13, 15, 16] . In 2011, the European Diabetes Working Party for Older People (EDWPOP) published a comprehensive set of guidelines that were evidence-based as far as possible, set glycaemic targets that were later adopted by many later guidelines and gave the first algorithm for glucose-lowering for frail people with Type 2 diabetes [7] . This was followed by the ADA and the European Association for the Study of Diabetes proposing a person-centred approach with individualization of targets based on the age of the person with diabetes and any comorbidities [56] . Other international guidelines followed [6, 8, [57] [58] [59] [60] (Table 2 ). The International Diabetes Federation global guidance on managing older people with Type 2 diabetes provided, for the first time, care recommendations for those with different categories of functional status and dependency including frailty [6] . The recent publication of an international Position Statement focusing on the management of frailty in diabetes provides clinicians with recommendations that may assist in the clinical management of a wide range of ill health-associated functional impairment characteristic of frailty [59] . Table S5 gives a general descriptive account of the guidelines shown in Table 2 .
Lifestyle interventions in older people with diabetes
Maintaining a healthy diet and activity level are important elements of diabetes care in older age, as in earlier life phases. A. Independent: 53-59 mmol/mol (7-7.5%). B. Dependent: 60-69 mmol/mol (7.6-8.5%).
A. Independent: < 140/80 mmHg. B. Non-frail > 80 years old: < 140-145/90 mmHg. C. Dependent: < 150/90 mmHg.
A. Statins generally recommended. B. Fibrates can be considered for high triglyceride in spite of statin therapy. AGS, 2012 [7] A. Healthy: < 59 mmol/mol (< 7.5%). B. Moderate morbidity: < 64 mmol/mol (< 8.0%). C. Severe morbidity: < 69 mmol/mol (< 8.5%). The limited number of studies that have been conducted on dietary interventions targeting older people have shown that nutritional education incorporating portion control, carbohydrate and lipid intake, meal spacing and nutritional awareness can improve metabolic outcomes [61, 62] . There is some limited evidence to show that in fitter older people, weight-reducing interventions with calorific restriction may also result in metabolic improvements [63, 64] , although compensatory exercise to ensure fat rather than muscle deposition needs to be considered [65] . It has also been noted that in older frailer people, intentional weight loss leads to bone and mineral depletion [66] . The nutritional needs of older people vary across groups and may be striking in those with co-morbid frailty, those with loss of the ability to prepare a meal or loss of appetite, and those with poor oral health [67] . These deficits may accelerate problems such as sarcopenia and reduce metabolic well-being [68] . Hence, the diet in the older person should be nutritionally dense, have an optimal protein intake, and be balanced in respect of micro-and macronutrients, which helps to preserve lean body mass [69] .
Body mass and physical stature may decline in older age making BMI a less reliable indicator of weight-related hazard [70] . A decline in body weight should be considered a significant risk factor, as it is associated with elevated mortality in the general and diabetes older populations [71, 72] . The ADA guideline advocates the use of the MiniNutritional Assessment scale which has been used to assess older people with diabetes [61] . Weight and waist circumference has been suggested as a more useful indicator in older people in assessing visceral fat and associated metabolic hazards [73] .
Evidence from the large diabetes prevention studies such as the US Diabetes Prevention Programme [74] , emphasized how an integrated lifestyle programme can have an enduring benefit. At 15 years post intervention, the lifestyle group had a 27% lower incidence of diabetes compared with the control group. The lifestyle cohort from the US Diabetes Prevention Programme have a mean age of 67 years, emphasizing the importance of exercise and weight reduction in the middle years to realize benefits in older age.
In terms of exercise intervention in older people with diabetes, a systematic review of these studies showed some benefits on skeletal muscle mass and diabetes outcomes [75] . Larger studies in the wider older age population have shown that structured physical activity intervention can significantly decrease age-related mental and physical disability [76] . In 2013, The Look AHEAD (Action for Health in Diabetes) trial [77] was the largest randomized trial evaluating a lifestyle intervention in obese or overweight older adults (aged 45-76 years) with Type 2 diabetes compared with a diabetes support and education control group. Unfortunately, no significant difference in cardiovascular events rates was observed. In 2016, the ADA published a Position Statement on physical activity and exercise in diabetes [78] , which concluded that both resistance training and aerobic exercise are required for optimizing glycaemic and other health outcomes.
Studies have also shown that inactivity in older age can contribute to metabolic dysfunction and accelerate the ageing process [79, 80] . Hence, continuing to provide older people with targeted lifestyle intervention is important to improve both their physical health and functioning.
Interventions for frailty in diabetes
Frailty is a dynamic condition that can worsen or improve over time [81] . Preventing sarcopenia may in turn prevent frailty [82] , but once frailty is established, the treatment requires regular functional assessments followed by timely multimodal interventions including adequate nutrition, physical exercise, managing glycaemia and the use of hypoglycaemic agents that have a high benefit to risk ratio. In the Women's Health and Aging Study II [83] , a HbA 1c ≥ 64 mmol/mol (≥ 8%) vs. < 37 mmol/mol (< 5.5%) was associated with an approximately threefold increased risk of incident frailty and three-to fivefold increased risk of lower extremity mobility limitations (all P < 0.05) measured at baseline in participants aged 70-79 years.
In the NHANES study [84] , up to 85% of the disability excess identified in those with diabetes was explained by the presence of comorbidities (mainly cardiovascular disease and obesity), and poor glucose regulation (HbA 1c ≥ 8%). However, the aim in managing older people with diabetes is to identify frailty early enough to stop disability developing in the first place.
Exercise interventions have beneficial effects on glycaemic control, muscle insulin sensitivity, intra-abdominal adipose tissue, muscle fat infiltration and on attenuating cardiovascular risk factors associated with diabetes [85] . In relation to older adults with diabetes, combined resistance and endurance training appears to serve as an effective exercise intervention to promote overall physical fitness [75, 86] and may even have a positive influence in those with dementia [87] . It is suggested that the exercise prescription for resistance training must be a frequency of one to six sessions per week, training volume of one to three sets of 6-15 repetitions, with an intensity of 30-70% one repetition maximum to promote significant enhancements in muscle strength, muscle power and functional outcomes [88] .
Two studies reported in the Lancet [89, 90] were important attempts to study the short-term benefits of glucose-lowering using DPP-4 inhibitors in 'frail' populations of older people with Type 2 diabetes. The first study was a randomized, double-blind, parallel-group phase 3 study [89] that examined the outcomes in terms of HbA 1c using linagliptin 5 mg or matching placebo in a group of highly comorbid older adults (n = 241; mean age 74.9 years). Tolerability was good and safety was similar in both groups, but at week 24, compared with placebo, the linagliptin group has a significant fall in HbA 1c of 0.64% (95% confidence interval: À0.81 to À0.48); unfortunately, despite this being a high-risk population, no objective measures of frailty were undertaken. The second study [90] was a similar double-blind, placebo-controlled, 24-week investigation of vildagliptin in adults aged ≥ 70 years (n = 278; mean age 75 years) with Type 2 diabetes, who were drug na€ ıve or inadequately controlled (HbA 1c 53-86 mmol/mol; 7-10%), and~1 in 10 were described as frail using a modified Fried's criteria assessment tool [91] . Each had been set individualized targets based on age, baseline HbA 1c , comorbidities and frailty status. This study showed that, compared with 27% in the placebo group, more than half (52.6%) of all those receiving vildagliptin met their set individualized targets (P < 0.0001) and had a between-group difference in HbA 1c fall of 0.6% (P < 0.0001), with a similar tolerability and safety.
More recently, the EU-funded multinational MID-FRAIL Trial [92] has been completed. Unpublished observations of this cluster randomized trial of resistance exercise and nutritional education (vs. usual care) in pre-frail and frail older people (n = 964; > 70 years) show a significant improvement in physical performance at 1 year (measured by changes in Short Physical Performance Battery scores) associated with reduced healthcare costs [93] .
Management strategies
Although diabetes management strategies for robust and high-functioning older adults should be similar to those for their younger counterparts [4, 6] , a safer, risk-stratification approach is required for those who are highly comorbid and/ or frail. The focus and main goals are described above (Box 1) but also require a quality use of medicines approach to be achieved [4, 6] . All treatment strategies require a riskbenefit analysis and the use of glucose-dependent strategies is preferred because they are less likely to cause unwanted hypoglycaemia, particularly in those with renal impairment [37] . A UK national stakeholder group has recently released a statement of the key principles of modern-day management of frail older adults with diabetes which focuses on the identification of frailty, reducing the vascular complications of diabetes and improving quality of life [94] .
Once functional, cardiovascular and diabetes-related complications assessments have been completed (post-assessment stage), and the treatment phase modulators have been applied, the individualized care approach can be realized, including setting glycaemic goals and blood pressure targets according to a multifactorial strategy (see Fig. 2 ). Although we indicate that life expectancy is an important influence in modulating goals, we accept that we have not discussed end of life as a specific management approach and how decisional capacity can affect planning care. Management of people with diabetes at end of life has been reviewed previously in detail by the lead author and others [6] .
For example, the clinician will balance the potential sideeffects of SGLT2 inhibitors or GLP-1 receptor agonists in older people with evidence relating to their proven cardiovascular benefits. The choice of using DPP-4 inhibitors will be a balance between minimal hypoglycaemia, lack of weight gain and broad use in renal impairment against neutral cardiovascular benefits. Insulin treatment can also be based on the use of NPH (wide experience, low cost, but higher hypoglycaemia risk) or the newer insulins such as glargine (U100/U300) or deglutec (U100/U200) -less glycaemic variability, lower hypoglycaemia risk, flexible timing but more expensive.
Preventing severe cardiovascular or renal disease and delaying the onset of frailty and disability require frequent review of nutritional status, exercise involvement, pharmacovigilance and the application of a deintensification programme where appropriate (Fig. 2) [95] . A recent Veteran Affairs Health System study of people with diabetes aged ≥ 70 years found that as many as one in five older people may be overtreated as evidenced by low HbA 1c levels (< 48 mmol/mol; < 6.5%) [96] . Deintensification (de-prescribing)
Box 4 Future research
Longer term observational studies
To assess cardiovascular risk with modern-day glucose-lowering treatment classes, particularly dipeptidyl peptidase-4 (DPP4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in different participant functional categories or complexities of illness as part of large prospective cohort studies. To assess: the impact of HbA 1c variability in the development of microvascular disease and frailty. Determine which HbA 1c and blood pressure targets provide the greatest benefit in different functional categories.
Development of clinical trial methodology
Instigate randomized clinical trials in primary care to examine the benefits of structured assessment and management pathways using appropriate primary and secondary outcome measures such as disability, cognitive dysfunction, frailty and quality of life. Apply comparative effectiveness research techniques to create new innovative clinical trial designs.
Randomized clinical trials of glucose lowering to a specific HbA 1c range
In high cardiovascular risk older people with Type 2 diabetes. In older people with Type 2 diabetes and stage 3 renal disease.
Randomized trials of multicomponent interventions
In people with sarcopenia to prevent frailty and disability. In people with functional loss, frailty and lower limb physical restrictions to improve physical performance and prevent immobility and loss of independence.
Influencing commissioners of clinical diabetes and geriatric services
Health economic analyses of interventions. Study designs that allow relevant and appropriate cost comparisons.
has thus become an important strategy for reducing the risks of overtreatment and hypoglycaemia, particularly in frail older people with Type 2 diabetes and multiple comorbidities, and may be achieved without undue harm and no loss of glycaemic control [95, [97] [98] [99] .
Future research: a call for action
In Box 4, we indicate key areas for future research that will address current shortfalls and gaps in evidence, and provide a framework for investment by pharmaceutical companies, medical research organizations, and diabetes and geriatric societies nationally and worldwide. New research directions must take into account the characteristics of older people with diabetes (increased risk of cardiovascular disease, renal impairment, polypharmacy and frailty), the likely complexity of illness management (see Fig. 1 ) and the inherent vulnerability to strict glucose lowering in terms of hypoglycaemia and premature mortality.
Research into the associations between functional class/ category of individuals (e.g. moderate or severe frailty) and HbA 1c and blood pressure targets, and their influence on clinical outcome are encouraged. We also recognize the need to study the effects of treatments on both traditional cardiovascular and functional outcomes, as shown in Box 4. What is becoming evident is that RCTs are becoming inefficient, complex, time-consuming and expensive, and the exclusion of various subgroups such as the 'elderly' imposes many restrictions on how healthcare policies can be reliably applied. Hence, a move to observational studies and more innovative clinical designs is encouraged.
Future research may need to focus on comparisons of effective interventions among people in typical care settings, with decisions tailored to individual needs, sometimes referred to comparative effectiveness research [100] , an initiative that requires new partnerships with industry, major pharma, private institutions and the public.
Summary of key conclusions
Compilation of this review has been challenging but immensely rewarding. It is obvious that there is increasing interest among clinical researchers, the pharmaceutical industry and government in how older people with Type 2 diabetes should be effectively managed to reduce excessive healthcare costs, and the impact on the individual with diabetes and their family and carers. There is now sufficient evidence and guidance available to present a framework of diabetes care that places an important emphasis on individualized care and how targets of care should be influenced by other factors such as functional status, the presence of frailty or cognitive impairment, and life expectancy. Further research into more innovative trail designs and the benefits of multicomponent interventions should also be encouraged.
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